The use of IV vitamin C for patients with COVID-19: a case series

Expert Rev Anti Infect Ther. 2020 Dec;18(12):1259-1261. doi: 10.1080/14787210.2020.1794819. Epub 2020 Aug 1.

Abstract

Background: The coronavirus disease 2019 (COVID-19) pandemic has affected almost 2.5 million people worldwide with almost 170,000 deaths reported to date. So far, there is scarce evidence for the current treatment options available for COVID-19. Vitamin C has previously been used for treatment of severe sepsis and septic shock. We reviewed the feasibility of using vitamin C in the setting of COVID-19 in a series of patients.

Methods: We sequentially identified a series of patients who were requiring at least 30% of FiO2 or more who received IV vitamin C as part of the COVID-19 treatment and analyzed their demographic and clinical characteristics. We compared inflammatory markers pre and post treatment including D-dimer and ferritin.

Results: We identified a total of 17 patients who received IV vitamin C for COVID-19. The inpatient mortality rate in this series was 12% with 17.6% rates of intubation and mechanical ventilation. We noted a significant decrease in inflammatory markers, including ferritin and D-dimer, and a trend to decreasing FiO2 requirements, after vitamin C administration.

Conclusion: The use of IV vitamin C in patients with moderate to severe COVID-19 disease may be feasible.

Keywords: COVID-19; coronavirus; mortality; sepsis; vitamin C.

MeSH terms

  • Administration, Intravenous
  • Aged
  • Anti-Inflammatory Agents / therapeutic use
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antiviral Agents / therapeutic use
  • Ascorbic Acid / therapeutic use*
  • COVID-19 / blood
  • COVID-19 / drug therapy*
  • COVID-19 / physiopathology
  • Drug Therapy, Combination
  • Feasibility Studies
  • Female
  • Ferritins / blood
  • Fibrin Fibrinogen Degradation Products / metabolism
  • Hospital Mortality
  • Humans
  • Hydroxychloroquine / therapeutic use
  • Hypoxia / physiopathology
  • Intubation, Intratracheal / statistics & numerical data
  • Male
  • Methylprednisolone / therapeutic use
  • Middle Aged
  • Respiration, Artificial / statistics & numerical data
  • Retrospective Studies
  • Severity of Illness Index
  • Vitamins / therapeutic use*

Substances

  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal, Humanized
  • Antiviral Agents
  • Fibrin Fibrinogen Degradation Products
  • Vitamins
  • fibrin fragment D
  • Hydroxychloroquine
  • Ferritins
  • tocilizumab
  • Ascorbic Acid
  • Methylprednisolone

Supplementary concepts

  • COVID-19 drug treatment

Grant support

This paper was not funded.